CYTOTROPIC HETEROGENEOUS MOLECULAR LIPIDS (LMHC), PREPARATION METHOD, AND METHODS FOR TREATING MULTIPLE CANCER PROTECTIVE PATIENTS

摘要

Cytotropic heterogeneous molecular lipids (LMHCs) are used to treat patients with multiple cancers. Many studies have been conducted in cell, animal, pre-clinical and clinical trials. The results show that LMHCs, as biological molecular missiles, can easily enter target cancer cells to cause programmed death of cancer cells (cancer apoptosis). In addition, LMHCs have produced anti-cancer angiogenesis and induced an increase in immune function. LMHCs have been used to treat 592 cancer patients in clinical trials. The results confirmed the following benefits of LMHC treatment: no toxicity, high response rate, excellent quality of life, and high survival rate of patients. Protocols included local injection, intra-arterial infusion and intravenous infusion to treat liver, lung, skin, breast, cerebral glioma, colorectal cancer, stomach cancer, head and neck cancer, leukemia, malignant lymphoma, sarcoma, malignant melanoma, myeloma, metastasized cancers, etc.